Your browser doesn't support javascript.
The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout.
Zaqout, Ahmed; Daghfal, Joanne; Alaqad, Israa; Hussein, Saleh A N; Aldushain, Abdullah; Almaslamani, Muna A; Abukhattab, Mohammed; Omrani, Ali S.
  • Zaqout A; Communicable Disease Center, Hamad Medical Corporation, Doha, Qatar; Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
  • Daghfal J; Communicable Disease Center, Hamad Medical Corporation, Doha, Qatar.
  • Alaqad I; Communicable Disease Center, Hamad Medical Corporation, Doha, Qatar.
  • Hussein SAN; Communicable Disease Center, Hamad Medical Corporation, Doha, Qatar.
  • Aldushain A; Communicable Disease Center, Hamad Medical Corporation, Doha, Qatar.
  • Almaslamani MA; Communicable Disease Center, Hamad Medical Corporation, Doha, Qatar; Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
  • Abukhattab M; Communicable Disease Center, Hamad Medical Corporation, Doha, Qatar; Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
  • Omrani AS; Communicable Disease Center, Hamad Medical Corporation, Doha, Qatar; Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar. Electronic address: aomrani@hamad.qa.
Int J Infect Dis ; 108: 116-118, 2021 Jul.
Article in English | MEDLINE | ID: covidwho-1351690
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT

OBJECTIVE:

This study examined the initial impact of a national BNT162b2 vaccine rollout on SARS-CoV-2 infections in Qatar.

METHODS:

All individuals who had completed ≥14 days of follow-up by 16 March 2021 after receiving the BNT162b2 vaccine were included. This study calculated incidence rates (IR) and their 95% confidence intervals (CI) during days 1-7, 8-14, 15-21, 22-28, and >28 days post-vaccination. Poisson regression was used to calculate incidence rate ratios (IRR) relative to the first 7-day post-vaccination period.

RESULTS:

A total of 199,219 individuals with 6,521,124 person-days of follow-up were included. SARS-CoV-2 infection was confirmed in 1877 (0.9%), of which 489 (26.1%) were asymptomatic and 123 (6.6%) required oxygen support. The median time from first vaccination to SARS-CoV-2 confirmation was 11.9 days (IQR 7.7-18.2). Compared with the first 7-day post-vaccination period, SARS-CoV-2 infections were lower by 65.8-84.7% during 15-21, 22-28, and >28 days (P < 0.001 for each). For severe COVID-19, the incidence rates were 75.7-93.3% lower during the corresponding time periods (P < 0.001 for each).

CONCLUSION:

The results were consistent with an early protective effect of BNT162b2 vaccine against all degrees of SARS-CoV-2 severity.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Int J Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: J.ijid.2021.05.021

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Int J Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: J.ijid.2021.05.021